Phoenix Life Sciences International Limited. (PLSI) 10-K 9 Apr 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Feb. 28, 2019	Aug. 31, 2019
Details
Registrant CIK	0001493212
Fiscal Year End	--02-28
Document Type	10-K
Document Annual Report	true
Document Period End Date	Feb. 28, 2019
Document Transition Report	false
Entity File Number	333-167275
Entity Registrant Name	Phoenix Life Sciences International Limited.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	46-0525378
Entity Address, Address Line One	4262 Blue Diamond Road #102-277
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89139
Entity Address, Address Description	Address of principal executive offices
Phone Fax Number Description	Company's telephone number, including area code
City Area Code	720
Local Phone Number	699-7222
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float		$ 26,429,744
Entity Common Stock, Shares Outstanding		10,762,097
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

Statement of Financial Position

Statement of Financial Position - USD ($)	Feb. 28, 2019	Feb. 28, 2018
ASSETS
Cash	$ 201,988	$ 697
Notes receivable, related party	0	235,752
Prepayments	2,169,269	0
Total Current Assets	2,371,257	236,449
Intellectual Property	8,766,356	0
Land deposit	299,000	0
Total Assets	11,436,613	236,449
Current Liabilities
Accounts payable and accrued liabilities	385,011	518,310
Pending cash settlements	500,000	0
Loan payable to Gauntlet	100,000	0
Other loans	36,172	0
Due to related parties	327,042	277,219
Current Liabilities	1,348,225	795,529
Convertible notes payable, net	0	415,581
Derivative liability, Typenex note	0	390,009
Total Liabilities	1,348,225	1,601,119
STOCKHOLDERS' DEFICIT
Common Stock, Value	10,085	34
Additional paid-in capital	34,100,397	17,785,335
Accumulated deficit during the development stage	(24,022,094)	(19,150,339)
Total Stockholders' Equity (Deficit)	10,088,388	(1,364,670)
Total Liabilities and Stockholders' Equity	11,436,613	236,449
Series B Preferred Stock
STOCKHOLDERS' DEFICIT
Preferred Stock, Value	0	200
Series C Preferred Stock
STOCKHOLDERS' DEFICIT
Preferred Stock, Value	$ 0	$ 100

Statement of Financial Positi_2

Statement of Financial Position - Parenthetical - $ / shares	Feb. 28, 2019		Feb. 28, 2018
Common Stock, Shares Authorized	990,000,000		990,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001
Common Stock, Shares, Issued	10,084,582	[1]	34,171
Common Stock, Shares, Outstanding	10,084,582	[1]	34,171
Series B Preferred Stock
Preferred Stock, Shares Issued	0		2,000,000
Preferred Stock, Shares Outstanding	0		2,000,000
Series C Preferred Stock
Preferred Stock, Shares Issued	0		995,600
Preferred Stock, Shares Outstanding	0		995,600
[1]	Following the Company’s determination that 22,500,000 shares issued to GHI Trustees Pty Ltd ATF The Global Health Trust were fraudulently issued and subsequently cancelled by the Board of Directors on August 23, 2019, it has been determined by the Board of Directors that, as these shares were erroneously issued in October 2018, they should be removed from stated results as at February 28, 2019, notwithstanding that the actual cancellation was effected on August 23, 2019.

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Feb. 28, 2019	Feb. 28, 2018
Details
Revenues	$ 0	$ 0
Cost of sales	0	0
Gross Profit	0	0
Operating expenses
Sales and marketing expenses	124,258	0
Operations expense	501,108	0
General and administrative	4,980	458
Consulting fees (includes non-cash consulting fees of $2,050,508)	2,196,341	0
Professional fees	207,348	0
Lease operating expenses	28,357	0
Total operating expenses	3,062,392	458
Loss before other expenses	(3,062,392)	(458)
Other income (expense)
Interest income	3	0
Miscellaneous income	974	0
Interest Expense	(49,442)	(83,064)
(Loss) on currency conversion	(6,335)	0
Gain on derivative liability	0	6,932
Total other expense	(54,800)	(76,132)
Net loss	$ (3,117,192)	$ (76,590)
Basic and diluted loss per common share
Income (loss) from continuing operations	$ (0.27)	$ (2.46)
Basic and diluted loss per common share	$ (0.27)	$ (2.46)
Weighted average shares outstanding - basic and diluted	11,630,774	31,118

Consolidated Statements of Op_2

Consolidated Statements of Operations - Parenthetical	12 Months Ended
	Feb. 28, 2019USD ($)
Details
Non-cash consulting fees	$ 2,050,508

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficiency / Equity - USD ($)	Common Stock	Preferred Stock	Receivables from Stockholder	Additional Paid-in Capital	Retained Earnings	Total
Equity Balance, Starting at Feb. 28, 2017			$ 0	$ 17,710,842	$ (19,073,749)	$ (1,362,576)
Equity Balance, Par Value, Starting at Feb. 28, 2017						$ 331
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 74,496		0	74,493	0
Stock Issued During Period, Shares, Conversion of Convertible Securities	3,104
Issuance of Common Stock for Warrant Conversion, Par Value	$ 3
Additional Paid-in Capital, Common Stock				17,785,637
Additional Paid-in Capital, Preferred Stock				(302)
Net Income (Loss)	$ (76,590)		0	0	(76,590)
Shares Outstanding, Ending at Feb. 28, 2018	34,171	2,995,600
Equity Balance, Par Value, Ending at Feb. 28, 2018	$ 34	$ 300				$ 334
Equity Balance, Ending at Feb. 28, 2018	$ (1,364,668)	$ (2)	0	17,785,335	(19,150,339)	$ (1,364,670)
Issuance of common stock from note payable, Value	$ 5,283		0	5,282	0
Issuance of common stock from note payable, Shares	900
Issuance of common stock from note payable, Par Value	$ 1
Issuance of common stock for true up of shares, Value	$ 131,250		0	131,237	0
Issuance of common stock for true up of shares, Shares	12,500
Par Value	$ 13
Issuance of common stock from merger, Value	$ 9,103,958		0	10,828,529	(1,754,563)
Issuance of common stock from merger, Shares	29,992,192
Issuance of common stock from merger, Par Value	$ 29,992
Issuance of common stock for services, Value	$ 487,695		0	487,500	0
Issuance of common stock for services, Shares	195,000
Issuance of common stock for services, Par Value	$ 195
Issuance of common stock for services and settlement, Value	$ 722,500		0	721,924	0
Issuance of common stock for services and settlement, Shares	575,583
Issuance of common stock for services and settlement, Par Value	$ 576
Issuance of common stock for services and settlement, Value	$ 457,699		0	457,470	0
Issuance of common stock for services and settlement, Shares	229,600
Issuance of common stock for services and settlement, Par Value	$ 229
Issuance of common stock for services and settlement, Value	$ 1,944,700		0	1,944,025	0
Issuance of common stock for services and settlement, Shares	675,028
Issuance of common stock for services and settlement, Par Value	$ 675
Issuance of common stock for settlement and in exchange of Series C Preferred Shares, Value	$ 500,600		0	500,099	0
Issuance of common stock for settlement and in exchange of Series C Preferred Shares, Shares	500,600
Issuance of common stock for settlement and in exchange of Series C Preferred Shares, Par Value	$ 501
Issuance of common stock for services and settlement, Value	$ 88,600		0	88,547	0
Issuance of common stock for services and settlement, Shares	53,080
Issuance of common stock for services and settlement, Par Value	$ 53
Issuance of common stock for services and settlement, Value	$ 1,150,463		0	1,150,147	0
Issuance of common stock for services and settlement, Shares	315,928
Issuance of common stock for services and settlement, Par Value	$ 316
Cancellation of erroneously issued shares, Value	$ (22,500)		0	0	0
Cancellation of erroneously issued shares, Shares	(22,500,000)
Cancellation of erroneously issued shares, Par Value	$ (22,500)
Cancellation of Series B, Value		$ 0	0	200	0
Cancellation of Series B, Shares		(2,000,000)
Cancellation of Series B, Par Value		$ (200)
Cancellation of Series C, Value		$ 2	0	102	0
Cancellation of Series C, Shares		(995,600)
Cancellation of Series C, Par Value		$ (100)
Net Income (Loss)	$ (3,117,192)		0	0	(3,117,192)
Shares Outstanding, Ending at Feb. 28, 2019	10,084,582	0				10,084,582
Equity Balance, Par Value, Ending at Feb. 28, 2019	$ 10,085	$ 0				$ 10,085
Equity Balance, Ending at Feb. 28, 2019	$ 10,088,388	$ 0	$ 0	$ 34,100,397	$ (24,022,094)	$ 10,088,388

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Feb. 28, 2019	Feb. 28, 2018
Operating Activities
Net loss	$ (3,117,192)	$ (76,590)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense on convertible notes payable	49,442	83,064
Non-cash (gain) on derivative liability	0	(81,428)
Debt conversion	5,283	74,496
Non-cash expenses of services & settlements	4,008,403	0
Changes in operating assets and liabilities:
Deposit on Land	(299,000)	0
Prepaid expense	(1,975,519)	0
Accounts payable and accruals	468,552	0
Net Cash (used for) operating activities - current operations	(860,030)	(458)
Investing Activities
Net Cash provided by (used for) Investing Activities - continuing operations	0	0
Other loans	41,730	0
Proceeds from issuance of common shares	1,019,591	0
Net Cash provided by Financing Activities - continuing operations	1,061,321	0
Increase (Decrease) in Cash - continuing operations	201,291	(458)
Cash and Cash Equivalents, at Carrying Value, Beginning Balance	697	1,155
Cash and Cash Equivalents, at Carrying Value, Ending Balance	201,988	697
Supplemental disclosures
Interest paid	0	0
Income tax paid	0	0
Non-cash issuance of stock for consulting agreement	2,196,341	0
Non-cash issuance of stock for prepaid expenses	$ 500,000	$ 0

1. Nature of Operations and Con

1. Nature of Operations and Continuance of Business	12 Months Ended
	Feb. 28, 2019
Notes
1. Nature of Operations and Continuance of Business	1. Nature of Operations and Continuance of Business The company was incorporated in the State of Nevada on April 21, 2009 under the name Mokita Exploration, Ltd. (the “Company”). On February 27, 2014, there was a change of control of the Company. On February 28, 2014, the board of directors and a majority of holders of the Company’s voting securities approved a change of name of the Company to MediJane Holdings Inc. A Certificate of Amendment to effect the change of name was filed and became effective with the Nevada Secretary of State on March 4, 2014. A Certificate of Correction was subsequently filed with the Nevada Secretary of State on March 6, 2014 to correct a spelling error in the Company’s new name. These amendments were approved by FINRA with an effective date of March 12, 2014. The name change became effective with the OTC Markets at the opening of trading on March 12, 2014 under our new ticker symbol "MJMD". On March 8, 2017 the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company changed its name with the State of Nevada from MediJane Holdings, Inc. to Stem Bioscience, Inc. In May 2018 the Company again changed its name, to become Phoenix Life Sciences International Limited. A Certificate of Amendment to effect the change of name was filed and became effective with the Nevada Secretary of State on May 31, 2018. The name change was accepted by FINRA and became effective with the OTC Markets Board on November 2, 2018 with the trading symbol “PLSI”. In September 2018, the Company completed a merger and consolidation with Phoenix Life Sciences International Limited (Canada). As part of the consolidation, the Series B Preferred Shares owned by Phoenix Bio Pharmaceuticals that were previously authorized to be cancelled were finally cancelled. Phoenix Life Sciences International Limited (Canada) had entered into asset purchase agreements with Phoenix Life Sciences Inc, Phoenix Bio Pharmaceuticals Corporation, Phoenix Pharms Capital Corporation and Phoenix Pharms Inc to consolidate all assets, liabilities, trade secrets, knowhow, diagrams and business plans, as well as all government relationships and pending contracts. Other than as specifically negotiated with former employees, contractors and officers, all shareholders were provided with a share exchange whereby they received one share of the Company for one share previously owned in one of these Companies. Pursuant to the Agreement and Plan of Merger, dated as of September 18, 2018 as (The “Merger Plan” by and between Phoenix Life Sciences International Limited, a Nevada Corporation (the “Company”) and Phoenix Life Sciences International Limited, a Canadian Corporation (“PLSI CA”), the Company completed its merger with PLSI CA, with the Company as the surviving entity. On September 18, 2018, the Company’s Board of Directors announced the finalized consolidation activities of Phoenix Life Sciences International Limited with Stem Biosciences, Inc., Blue Dragon Ventures, and the MediJane Brand, and that the Company’s common stock would trade publicly under the symbol MJMD, subsequently on November 2, 2018 this changed to PLSI. Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) commenced the consolidation of business in 2018. During that time, affiliates of the Company provided certain working capital and covering of costs related to the consolidation. Subsequently the Company entered into subscription agreements with certain affiliates and key non-affiliate investors to provide a total of approximately USD $2.1million of financing. Shares of common stock issued for this total financing represent approximately 800,000 common stock shares. The key non-affiliate investor who had previously entered into a subscription agreement to purchase USD $20 million of shares at $10 per share with Phoenix Life Sciences International Limited (Canada) has entered into an agreement to exchange the subscription for warrants to purchase Company common stock at a price of $10, with the purchases to be completed by December 31, 2019. This agreement is currently under negotiation to extend the timeframe Further, as part of the merger and consolidation, Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) entered into settlement agreements with former investors, employees and contractors whereby their debt, shares held in entities subject of the consolidation, or outstanding amounts were settled in exchange for a full release of claims and the Company issuing approximately eight (8) million shares and the assumption of approximately $2 million of settlements payable. The purpose of the consolidation, in addition to providing the deemed necessary relationships and contracts for the Company to execute on its strategy, was to settle any potential claim or liability to ensure that the Company was not subject to any claims by former investors, employees and contractors. On September 22, 2018, the Company’s Board of Directors accepted the resignation of Russell Stone from his position as a Director. On October 3, 2018, the following persons were appointed to the Board of Directors of the Company: Stephen Cornford, Martin Tindall as Chief Executive Officer, Janelle Marsden as Managing Director and Geoffrey Boynton as Chief Financial Officer. Lewis “Spike” Humer stepped down from his executive role but remains a Director. On July 11, 2019, the Board of Directors confirmed that Martin Tindall had been placed on indefinite, unpaid suspension from his position as Chief Executive Officer and removed any and all authorities given to him by the Company. Concurrently, the Company’s Board of Directors appointed Janelle Marsden, to the role of Interim Chief Executive Officer. On August 27, 2019, the Board of Directors permanently removed Martin Tindall from his role as Chief Executive Officer. Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company’s total operating expenditure plan for the following twelve months will require significant cash resources to meet the goals of its business plan. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Feb. 28, 2019
Notes
2. Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation - Basis of Consolidation Use of Estimates - Other items subject to estimates and assumptions include accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates. Cash and cash equivalents - Accounts receivable Intellectual Property Prepaid Assets Other Loans Basic and Diluted Net Loss per Share - Earnings per Share Financial Instruments - Fair Value Measurements and Disclosures Level 1 - Level 2 - Level 3 - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Derivative Financial Instruments - The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date. Stock-based Compensation - Compensation – Stock Based Compensation Equity-Based Payments to Non-Employees The fair value of each Options based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. Expected Volatility. Dividend Yield. Expected Term. Forfeitures. Revenue Recognition – Leases Leases, Shipping and Handling costs — shipping and handling costs are included in cost of sales in the Statements of Operations. Recent Accounting Pronouncements - Reclassifications -

3. Intangible Assets

3. Intangible Assets	12 Months Ended
	Feb. 28, 2019
Notes
3. Intangible Assets	3. Intangible Assets In September 2018, the Company with the merger of Phoenix Life Sciences International Limited (Canada), a related party due to common management, acquired all of the assets and liabilities of Phoenix Life Sciences International Limited (Canada) including intellectual property totaling $8,766,356, which consisted of trade secrets, know how, concepts to be patented for the creation of a series of formulations, specific genetic plant selection, delivery systems designed by botanists, biologists, chemical and industrial engineers for the purposes of maximizing the efficacy of medical cannabis for the targeted treatment of specific diseases, including diabetes, cancers, neurological and phycological disorders, autoimmune diseases, as well as a series of generic medical cannabis products for doctor prescription. All products are designed to be produced to pharmaceutical (cGMP) standards and to be regulated as a controlled substance. The intangibles asset will amortized on a straight basis over the expected useful period of 10 years. As of February 29, 2019, amortization has not commenced. In addition, the intangible assets are tested for impairments annually. There were no impairments for the year ended February 29, 2019. Proprietary formulations for the treatment of diabetes, various cancers, neurological and phycological disorders and autoimmune diseases $ 7,500,000 Professionally developed delivery systems maximizing the efficacy of medical cannabis treatments $ 1,000,000 Other trade secrets $ 266,356 Total $ 8,766,356

4. Deferred Tax Asset

4. Deferred Tax Asset	12 Months Ended
	Feb. 28, 2019
Notes
4. Deferred Tax Asset	4. Deferred Tax Asset The deferred tax assets or liabilities represent the future tax benefits or cost of those differences. The Company’s principal deferred tax items arise from net operating losses. Net operating losses approximate $24,174,826 which expire in the years 2030 through 2039. The net operating loss results in a deferred tax asset of $3,626,000. As future earnings are uncertain, the Company has provided a valuation allowance for the entire amount of the deferred tax asset. The Company is required to evaluate the tax positions taken in the course of preparing its tax returns to determine whether tax positions are “more likely than not” of being sustained by the applicable tax authority “More likely than not” is defined as greater than a 50% chance. The Company is delinquent on nearly all of its tax filings. As a result, there are presently no uncertain tax position and no reserves for uncertain tax positions. The Company has no unrecognized tax benefits at February 28, 2019 and February 28, 2018. The Company’s income tax returns are subject to examination by federal and state tax authorities. Due to the failure to file its tax returns, all prior tax years are open to examination. The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the balance sheet. There were no interest and penalties paid or accrued during the years ended February 28, 2019 and February 28, 2018. The Company expects no significant effects from the tax Cuts and Jobs Act for the current reporting period.

5. Subsidiary Companies

5. Subsidiary Companies	12 Months Ended
	Feb. 28, 2019
Notes
5. Subsidiary Companies	5. Subsidiary Companies On March 17, 2014, MediHoldings, Inc. (“MediHoldings”), a Colorado corporation, was formed as a wholly-owned subsidiary of the Company. On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly-owned subsidiary of the Company. Both these subsidiaries as at February 28, 2019 had not traded and were inactive. On September 18, 2018, with the merger with Phoenix Life Sciences International Limited (Canada), the Company gained an Australian Incorporated subsidiary, Phoenix Life Sciences (Australia) Pty Ltd.

6. Related Party Transactions

6. Related Party Transactions	12 Months Ended
	Feb. 28, 2019
Notes
6. Related Party Transactions	6. Related Party Transactions Russell Stone Mr. Russell Stone, the Company’s former Chief Operating Officer, entered into a settlement agreement with the Company for unpaid services where he would be paid $125,000 over a maximum of 24 months. As at February 28, 2019, Mr. Stone was still owed $70,000. Mr. Stone prior held approximately 14% of the outstanding common shares of Phoenix Pharms Capital Corporation (PPCC) indirectly through a trust, prior to PPCC being sold into Phoenix Life Sciences International Limited (a Canadian Corporation). On September 22, 2018, the Company’s Board of Directors accepted the resignation of Russell Stone from his position as a Director. Martin Tindall Mr. Martin Tindall joined the Board as Chief Executive Officer on October 3, 2018. Previously Mr. Tindall had assisted Company with business development activities through the Advisory Services Agreement. Mr. Tindall serviced as CFO and a Director of Phoenix Pharms Capital Corporation, a director of Phoenix Bio Pharmaceuticals Inc. and a director and shareholder of Phoenix Life Sciences International Limited (a Canadian Corporation); which were all vended into the Company on September 18, 2018 as a result of the Company’s Merger with Phoenix Life Sciences International Limited (Canada). Lewis “Spike” Humer Mr. Lewis “Spike” Humer was previously the interim Chief Executive Officer and a director of the Company. After the merger he stepped down from an executive role but remains on the Board and has been appointed Non-executive Chairman. He also previously served as CEO and a director of Phoenix Bio Pharmaceuticals and CEO and a director of Phoenix Pharms Capital Corporation, which were part of the merger. A settlement agreement has been reached with Mr. Humer for unpaid services, prior to the merger where he would pay $125,000 plus $5,000 in unpaid expenses with the money to be paid over a maximum of 24 months and issued 100,000 common shares in the Company. Mr. Humer was owed $85,000 as at February 28, 2019.

7. Common Stock

7. Common Stock	12 Months Ended
	Feb. 28, 2019
Notes
7. Common Stock	7. Common Stock The Company has authorized 990,000,000 shares of its common stock, $0.001 par value. On February 28, 2018, there were 34,171 shares of common stock issued and outstanding. On September 24, 2018, the Company issued 29,992,192 shares of common stock bearing the restricted legend without registration (the “Issued Shares”). Of these, 29,292,192 shares were issued in reliance on Rule 802 under the Securities Act in a 1:1 share exchange related to the merger of PLSI CA and the company as described above, and 700,000 shares were issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. All of the Issued Shares were issued in private transactions, and the company received no proceeds from the Issued Shares. On October 03, 2018, the Company agreed to issue 48,000 shares of restricted common stock to KHAOS Media Group as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act for services previously rendered and invoiced between March and December 2014. A further 147,000 shares were issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act for services post those dates. On October 18, 2018, the Company issued 575,583 common shares as part of settlement agreements. On December 4, 2018, the Company issued 229,600 common shares as part of settlement agreements. On December 17, 2018, the Company issued 675,028 common shares which included 191,668 common shares as part of settlement agreements and 483,360 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act On January 11, 2019, the Company issued 500,600 common shares to YP Holding, LLC. as part of a settlement agreement and conversion of Series C preferred shares. On January 15, 2019 the Company issued 53,080 common shares which included 52,000 common shares as part of settlement agreements and 1,080 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act On February 26, 2019 the Company issued 315,928 common shares which included 5,460 common shares as part of settlement agreements, 126,750 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act and 183,718 for cash consideration. In August it was determined, after inquiries of solicitors in Vanuatu and Australia, that 22,500,000 common shares had been issued fraudulently, consequently the Board of Directors cancelled these 22,500,000 common shares. As at February 28, 2019 the adjusted shares on issue, excluding the fraudulently issued shares, were 10,084,582 common shares on issue.

8. Preferred Stock

8. Preferred Stock	12 Months Ended
	Feb. 28, 2019
Notes
8. Preferred Stock	8. Preferred Stock On July 8, 2015, the Company approved the creation of four classes of preferred stock. · · · · On November 4, 2015, Phoenix Bio Pharmaceuticals Corporation were issued 2,000,000 Series B Preferred Shares in exchange for 27,600 common shares (27,600,000 pre-split). As at February 28, 2018, Phoenix Bio Pharmaceuticals Corporation held 2,000,000 Series B Preferred Shares. On September 21, 2018, the Company announced it had obtained consent from the holder, Phoenix Bio Pharmaceuticals Corporation for the cancellation of 2,000,000 Preferred Series B shares in the Company in connection with the restructure of the Company and merger with Phoenix Life Sciences International Limited, a Canadian Corporation therefore there were no Series B Preferred Shares on issue at February 28, 2019. On February 18, 2016, YP Holdings, LLC was issued 1,000,000 Series B Preferred Shares in exchange for 667 common shares (6,666,667 pre-split). As at February 28, 2018 YP Holdings LLC had been issued 1,000,000 Series C Preferred Shares, but had converted 4,400 into common shares and therefore held 995,600 Series C Preferred Shares. However subsequently agreement was reached to cancel all outstanding Series C Preferred Shares. On January 11, 2019, the Company issued 500,600 common shares to YP Holdings LLC as part of a settlement agreement which included the return and cancellation of 995,600 Series C Preferred Shares There was no outstanding preferred stock on issue as at February 28, 2019

9. Convertible Promissory Note

9. Convertible Promissory Note	12 Months Ended
	Feb. 28, 2019
Notes
9. Convertible Promissory Note	9. Convertible Promissory Note On or about June 24, 2014, the Company entered into a Convertible Promissory Note with a face value of $1,105,000 (the “Note”) by and between the Company and Typenex Co-Investment, LLC (“Typenex”). On or about April 19, 2018, the Phoenix Life Sciences International Ltd, a Canadian Corporation (“PLSI CA”) acquired the entirety of the Notes outstanding principal and interest balance from Typenex. Upon the completion of the merger, that Note was conveyed to the Company. On September 22, 2018, the Company’s Board of Directors resolved to deem the acquired Notes principal balance satisfied, and to terminate the Note and any and all rights and obligations arising thereunder, including without limitation the cancellation of all outstanding Warrants issued to Typenex under the Note. This also meant that the derivative liability carried on the balance sheet was retired.

10. Securities Purchase Agreeme

10. Securities Purchase Agreement	12 Months Ended
	Feb. 28, 2019
Notes
10. Securities Purchase Agreement	10. Securities Purchase Agreement On September 17, 2014, the Company entered into a securities purchase agreement with YP Holdings, LLC. YP Holdings, LLC has no material relationship with the Company other than with respect to this agreement. Under this agreement, the purchasers will be purchasing units of one common share and two warrants to purchase common shares for $0.09 per unit, for a total of $600,000. The common shares have a par value of $0.001 per share. The warrants are exercisable for five years from the date of issuance and shall have an initial exercise price equal to $0.20. As a result of this agreement, the Company issued 6,666,667 common shares and 13,333,334 warrants to the purchasers. On August 29, 2014 and September 17, 2014, the Company received gross proceeds of $100,000 and $500,000, respectively and has recorded financing fees of $18,000 and $52,000, related to this agreement. The warrants can be exercised by paying the price for shares as stipulated by the warrant, or through cashless exercise, through which the purchaser will be issued a number of shares equal to the number of warrant shares applied to the subject exercise multiplied by the current market price on the date of conversion minus the exercise price on that date. This total is then divided by the current market price on the date of conversion. The cashless exercise may only be exercised after six months have passed from the original issuance of the warrants. The purchaser has waived the clause prohibiting conversion of warrants into common shares if that would result in the purchaser owning in excess of 4.99% of the outstanding shares. A second clause prohibits the conversion of warrants if the purchaser owns in excess of 9.99% of the outstanding common shares. This clause can be waived by the purchaser providing notice of waiver. The Company has agreed to pay a flat $20,000 to YP Holdings, LLC to reimburse them for the fees and expenses incurred by it in connection with its due diligence review of the Company and the preparation, negotiation, executive, delivery and performance of the agreement. The two parties also entered into a registration rights agreement. Under this agreement, the Company will prepare and file a registration statement on Form S-1 in order to register all shares issued under the securities purchase agreement. The Company will keep the registration statement continuously effective for a period of two years following the effective date of the registration statement. The Company will pay all reasonable fees and expenses incurred with respect to this agreement. Unless previously agreed to in writing, the Company may not register any shares other than those intended to be sold under this agreement. Should the Company fail to comply with the registration rights agreement, the Company agrees to pay liquidated damages to YP Holdings, LLC equal to 3% of the purchase price of the common shares paid by the purchaser for the first 30 day period, and 2% of such purchase price for each subsequent 30 day period. These payments are payable upon demand in cash. Pursuant to the registration rights agreement, the Company agreed to several lock-up agreements between itself and four shareholders of the Company: Phoenix Bio Pharmaceuticals Corporation, Ronald Lusk, Lewis Humer, and Caduceus Industries LLC. Under these agreements, each shareholder has agreed that they will not offer, pledge, sell, contract to sell, grant any options for sale or transfer, distribute or dispose of, directly or indirectly, any shares of the Company for a 90 day period following the date that the registration statement is declared effective. On February 18, 2016, YP Holdings, LLC was issued 1,000,000 Series B Preferred Shares in exchange for 667 common shares. On February 28, 2016 YP Holdings, LLC converted 2,000 preferred shares into 2,000 common shares and on March 4, 2016, a further 2,400 preferred shares into common shares. A settlement has been reached in respect of this liability. In exchange for 500,600 common shares, 995,600 Series C Preferred Shares were return to us for cancellation and both parties agreed that there were no further obligations.

11. Subsequent Events

11. Subsequent Events	12 Months Ended
	Feb. 28, 2019
Notes
11. Subsequent Events	11. Subsequent Events On April 2, 2019, we issued 151,216 common stock shares for cash consideration. On April 25, 2019, we issued 100,000 common stock shares for cash consideration. On May 1, 2019, we signed a Memorandum of Understanding with the Ministry of Health on behalf of The Republic of Vanuatu for the purposes of establishing a public-private partnership for the health and well-being of Ni-Vanuatu people, further the Memorandum of Understanding provides for Phoenix Life to have a 25 year exclusive contract for the supply of diabetes management and the supply of Phoenix Metabolic to the countries estimated 50,000 diabetics. Based solely upon a charge rate of $25 per patient per month, this agreement would provide Phoenix Life with the potential of $300 million US dollars in revenue and reduction in excise duty. Due to the material risks disclosed herein and whether we have sufficient funding to accomplish our operational goals, there are absolutely no assurances that we will attain that level of revenues. The agreement further provides for the issuance of production and distribution licensing for Phoenix Life to produce in Vanuatu and distribute around the world both generic medical cannabis products for doctors’ prescription and for Phoenix Life’s products that are approved for specifically treating specific diseases. Lastly the agreement provides a fast track clinical development program, including building a national network of community clinics and dispensing pharmacies throughout the Republic of Vanuatu. On May 9, 2019, we issued 155,452 common stock shares, which included 17,929 common stock shares issued for cash consideration and 137,523 common stock shares as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. On May 24, 2019, we issued 126,990 common stock shares which included 112,590 common stock shares for cash consideration and 14,400 common stock shares as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. On May 30, 2019, we signed a Memorandum of Understanding with the Ministry of Agriculture on behalf of The Republic of Vanuatu for the purposes of establishing a public-private partnership to establish the terms and conditions under which the Republic of Vanuatu shall provide at least 5,000 acres of land on the Island of Espiritu Santo for the exclusive use of the Company for large scale cultivation of medical cannabis over a seventy-five (75) year period. We will be granted a license by the Government for the cultivation, processing, extraction and pharmaceutical production of medical cannabis and in exchange we will pay the Republic of Vanuatu ten (10) percent of net revenue earned through the use of this land and license. On May 30, 2019, we signed a Memorandum of Understanding with the Ministry of Agriculture on behalf of The Republic of Vanuatu for the purposes to establish the terms and conditions under which the Company will be permitted (1) to establish and operate a plant quarantine facility on the site of the Vanuatu Agricultural Research and Technical Centre (VARTC); (2) to perform medical cannabis research at the VARTC facility; and (3) to present a medical cannabis training curriculum for the Vanuatu Agricultural College. On June 17, 2019 we entered into a 10% Convertible Promissory Note (the “Note”) for the Principal Sum of $220,000 by and between the Company and Harbor Gates Capital, LLC (the “Holder”). For value received, the Company hereby promises to pay to the order of Harbor Gates Capital, LLC or its registered assigns or successors-in-interest (the “Holder”) the Principal Sum of $220,000 (the “Principal Sum”) and to pay “guaranteed” interest on the principal balance hereof at an amount equivalent to 10% of the Principal Sum, to the extent such Principal Sum and “guaranteed” interest and any other interest, fees, liquidated damages and/or items due to Holder herein have not been repaid or converted into the Company's common stock (the “Common Stock”), in accordance with the terms of the Note. As an investment incentive, the Company will issue to the Holder 5,000 common stock shares as restricted Incentive Shares (the “Origination Shares”), which shares shall be issued in the Holder’s name within 10 Trading Days of the Date of Execution. “Conversion Price” of the Note shall be equal to 70% of the lowest trading price of the Company’s Common Stock during the 20 consecutive Trading Days prior to the date on which Holder elects to convert all or part of the Note. Repayment (a) Days Since Effective Date Payment Amount Under 90 120% of Principal Amount so paid 91-180 130% of Principal Amount so paid (b) On June 24, 2019, we issued 28,500 common stock shares which included 13,500 common stock shares for cash consideration and 15,000 common stock shares as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. On June 24, 2019, the Board of Directors granted Martin Tindall a temporary leave of absence from his position as Chief Executive Officer and Director of the Company to address certain unforeseen personal issues. Concurrently, the Company’s Board of Directors appointed Janelle Marsden, the Company’s Managing Director, to the role of Interim Chief Executive Officer until such time as Mr. Tindall is able to resume his position, or the Board of Directors appoints an alternate Chief Executive Officer. Subsequently on July 11, 2019, the Board of Directors confirmed that Martin Tindall had been arrested and charged with securities fraud in the State of Colorado. Following research by counsel, the Company determined that the charges predated Mr. Tindall’s activities with the Company, and that none of charges were directly related to his activities with the Company. However, due to the nature of the charges, the Board of Directors publicly confirmed that Martin Tindall was placed on indefinite, unpaid suspension from his position as Chief Executive Officer and removed any and all authorities given to him by the Company. Concurrently, the Company’s Board of Directors appointed Janelle Marsden, to the role of Chief Executive Officer. On July 23, 2019, we issued 92,690 common shares which included 40,690 for cash consideration and 52,000 common shares as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. On August 5, 2019, Michael Gobel resigned as Director of the Company, due to other work commitments. In August it was determined, after inquiries of solicitors in Vanuatu and Australia, that 22,500,000 common shares had been issued erroneously, consequently the Board of Directors cancelled these 22,500,000 common shares. On August 22, 2019, we issued 40,000 Series B Preferred Shares (the “Preferred Shares”) to entities associated with each of the five members of a Special Committee composed of our Board Members and Stacey Jenkins, and not including Martin Tindall, that are convertible into a total of 20,000,000 common stock shares. The 20,000,000 common stock shares that may be converted from the Preferred Shares constitutes 65.06% of our 30,739,730 outstanding shares upon conversion, which shares are subject to a 12 months lockup and resale restriction of shares per financial quarter. On August 27, 2019, pursuant to provision 4.5 of our bylaws and a Board meeting of that same date, our Board permanently removed Martin Tindall as our Chief Executive Officer and/or any other of our officer positions or that of our subsidiaries. On August 27, 2019, our Board of Directors adopted the following: a) b) c) d) e) On August 27, 2019, our Board of Directors appointed the following Board Members to our Audit Committee, Compensation Committee, and Nominating Committee: Audit Committee Lewis Humer Geoff Boynton Compensation Committee Lewis Humer Stephen Cornford Nominating Committee Lewis Humer Janelle Marsden On August 27, 2019, we issued 22,667 common shares which included 7,667 for settlement consideration and 15,000 common shares as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. On November 11, 2019, Constantine and Suzanne Makris were granted a default judgement against the Company for $165,000 plus $6,957.76 in costs against the Company. As at February 28, 2019 had a recorded liability of $365,000 and subsequently $200,000 was paid.

12. Commitments and Contingenci

12. Commitments and Contingencies	12 Months Ended
	Feb. 28, 2019
Notes
12. Commitments and Contingencies	12. Commitments and Contingencies Pursuant to Chief Executive Officer Marsden’s investigation, she learned that on October 29, 2018, Gauntlet Holdings, LLC (“Gauntlet”) and NMS Capital Advisors, LLC (“NMS”) filed a lawsuit against us and our then Chief Executive Officer, Martin Tindall, for breach of contract and fraudulent misrepresentation in connection with an alleged default upon a Secured Promissory Note ( Gauntlet Holdings, LLC et al vs. Kronos International, Phoenix Life Sciences International Limited, Medijane Holdings, Martin Tindall, Vincent Coviello Pursuant to Chief Executive Officer Marsden’s investigation, she discovered that on January 30, 2019, Terrence Roderick Hannam filed a lawsuit against us for breach of contract in connection with an agreement that we would acquire all shares of Silver Holdings, Ltd. ( Terrence Roderick Hannam v. Phoenix Life Sciences International, Limited

1. Nature of Operations and C_2

1. Nature of Operations and Continuance of Business: Going Concern (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Going Concern	Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company’s total operating expenditure plan for the following twelve months will require significant cash resources to meet the goals of its business plan. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Acc_2

2. Summary of Significant Accounting Policies: Basis of Presentation (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Basis of Presentation	Basis of Presentation -

2. Summary of Significant Acc_3

2. Summary of Significant Accounting Policies: Basis of Consolidation (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Basis of Consolidation	Basis of Consolidation

2. Summary of Significant Acc_4

2. Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Use of Estimates	Use of Estimates - Other items subject to estimates and assumptions include accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates.

2. Summary of Significant Acc_5

2. Summary of Significant Accounting Policies: Cash and cash equivalents (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Cash and cash equivalents	Cash and cash equivalents -

2. Summary of Significant Acc_6

2. Summary of Significant Accounting Policies: Accounts receivable (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Accounts receivable	Accounts receivable

2. Summary of Significant Acc_7

2. Summary of Significant Accounting Policies: Intellectual Property (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Intellectual Property	Intellectual Property

2. Summary of Significant Acc_8

2. Summary of Significant Accounting Policies: Prepaid Assets (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Prepaid Assets	Prepaid Assets

2. Summary of Significant Acc_9

2. Summary of Significant Accounting Policies: Other Loans (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Other Loans	Other Loans

2. Summary of Significant Ac_10

2. Summary of Significant Accounting Policies: Basic and Diluted Net Loss per Share (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share - Earnings per Share

2. Summary of Significant Ac_11

2. Summary of Significant Accounting Policies: Financial Instruments (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Financial Instruments	Financial Instruments - Fair Value Measurements and Disclosures Level 1 - Level 2 - Level 3 - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

2. Summary of Significant Ac_12

2. Summary of Significant Accounting Policies: Derivative Financial Instruments (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Derivative Financial Instruments	Derivative Financial Instruments - The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date.

2. Summary of Significant Ac_13

2. Summary of Significant Accounting Policies: Stock-based Compensation (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Stock-based Compensation	Stock-based Compensation - Compensation – Stock Based Compensation Equity-Based Payments to Non-Employees The fair value of each Options based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:

2. Summary of Significant Ac_14

2. Summary of Significant Accounting Policies: Risk-Free Interest Rate (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Risk-Free Interest Rate	Risk-Free Interest Rate.

2. Summary of Significant Ac_15

2. Summary of Significant Accounting Policies: Expected Volatility (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Expected Volatility	Expected Volatility.

2. Summary of Significant Ac_16

2. Summary of Significant Accounting Policies: Dividend Yield (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Dividend Yield	Dividend Yield.

2. Summary of Significant Ac_17

2. Summary of Significant Accounting Policies: Expected Term (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Expected Term	Expected Term.

2. Summary of Significant Ac_18

2. Summary of Significant Accounting Policies: Forfeitures (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Forfeitures	Forfeitures.

2. Summary of Significant Ac_19

2. Summary of Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Revenue Recognition	Revenue Recognition –

2. Summary of Significant Ac_20

2. Summary of Significant Accounting Policies: Leases (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Leases	Leases Leases,

2. Summary of Significant Ac_21

2. Summary of Significant Accounting Policies: Shipping and Handling costs (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Shipping and Handling costs	Shipping and Handling costs — shipping and handling costs are included in cost of sales in the Statements of Operations.

2. Summary of Significant Ac_22

2. Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements -

2. Summary of Significant Ac_23

2. Summary of Significant Accounting Policies: Reclassifications (Policies)	12 Months Ended
	Feb. 28, 2019
Policies
Reclassifications	Reclassifications -

3. Intangible Assets_ Schedule

3. Intangible Assets: Schedule of Finite-Lived Intangible Assets (Tables)	12 Months Ended
	Feb. 28, 2019
Tables/Schedules
Schedule of Finite-Lived Intangible Assets	Proprietary formulations for the treatment of diabetes, various cancers, neurological and phycological disorders and autoimmune diseases $ 7,500,000 Professionally developed delivery systems maximizing the efficacy of medical cannabis treatments $ 1,000,000 Other trade secrets $ 266,356 Total $ 8,766,356

1. Nature of Operations and C_3

1. Nature of Operations and Continuance of Business (Details)	12 Months Ended
	Feb. 28, 2019
Details
Entity Incorporation, State or Country Code	NV
Entity Incorporation, Date of Incorporation	Apr. 21, 2009

3. Intangible Assets_ Schedul_2

3. Intangible Assets: Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Feb. 28, 2019	Feb. 28, 2018
Intangible Assets	$ 8,766,356	$ 0
Proprietary formulations for the treatment of diabetes, various cancers, neurological and phycological disorders and autoimmune diseases
Intangible Assets	7,500,000
Professionally developed delivery systems maximizing the efficacy of medical cannabis treatments
Intangible Assets	1,000,000
Other trade secrets
Intangible Assets	$ 266,356

4. Deferred Tax Asset (Details)

4. Deferred Tax Asset (Details)	Feb. 28, 2019USD ($)
Details
Deferred Tax Assets, Net of Valuation Allowance	$ 3,626,000

5. Subsidiary Companies (Detail

5. Subsidiary Companies (Details)	12 Months Ended
	Feb. 28, 2019
MediHoldings, Inc
Business Acquisition, Effective Date of Acquisition	Mar. 17, 2014
MediSales (CA), Inc
Business Acquisition, Effective Date of Acquisition	Jun. 27, 2014
Phoenix Life Sciences (Australia) Pty Ltd
Business Acquisition, Effective Date of Acquisition	Sep. 18, 2018

6. Related Party Transactions (

6. Related Party Transactions (Details)	Feb. 28, 2019USD ($)
Mr. Russell Stone, the Company's former Chief Operating Officer
Due to Officers or Stockholders	$ 70,000
Mr. Lewis "Spike" Humer
Due to Officers or Stockholders	$ 85,000

7. Common Stock (Details)

7. Common Stock (Details) - $ / shares	12 Months Ended
	Feb. 28, 2019		Feb. 28, 2018
Common Stock, Shares Authorized	990,000,000		990,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001
Common Stock, Shares, Outstanding	10,084,582	[1]	34,171
Common Stock, Shares, Issued	10,084,582	[1]	34,171
Transaction #1
Sale of Stock, Transaction Date	Sep. 24, 2018
Sale of Stock, Description of Transaction	Company issued 29,992,192 shares of common stock bearing the restricted legend without registration (the “Issued Shares”)
Stock Issued During Period, Shares, New Issues	29,992,192
Transaction #2
Sale of Stock, Transaction Date	Oct. 3, 2018
Sale of Stock, Description of Transaction	Company agreed to issue 48,000 shares of restricted common stock to KHAOS Media Group as compensation for services rendered
Stock Issued During Period, Shares, New Issues	48,000
Transaction #3
Sale of Stock, Transaction Date	Oct. 18, 2018
Sale of Stock, Description of Transaction	Company issued 575,583 common shares as part of settlement agreements
Stock Issued During Period, Shares, New Issues	575,583
Transaction #4
Sale of Stock, Transaction Date	Dec. 4, 2018
Sale of Stock, Description of Transaction	Company issued 229,600 common shares as part of settlement agreements
Stock Issued During Period, Shares, New Issues	229,600
Transaction #5
Sale of Stock, Transaction Date	Dec. 17, 2018
Sale of Stock, Description of Transaction	Company issued 675,028 common shares
Stock Issued During Period, Shares, New Issues	675,028
Transaction #6
Sale of Stock, Transaction Date	Jan. 11, 2019
Sale of Stock, Description of Transaction	Company issued 500,600 common shares to YP Holding, LLC.
Stock Issued During Period, Shares, New Issues	500,600
Transaction #7
Sale of Stock, Transaction Date	Jan. 15, 2019
Sale of Stock, Description of Transaction	Company issued 53,080 common shares
Stock Issued During Period, Shares, New Issues	53,080
Transaction #8
Sale of Stock, Transaction Date	Feb. 26, 2019
Sale of Stock, Description of Transaction	Company issued 315,928 common shares
Stock Issued During Period, Shares, New Issues	315,928
[1]	Following the Company’s determination that 22,500,000 shares issued to GHI Trustees Pty Ltd ATF The Global Health Trust were fraudulently issued and subsequently cancelled by the Board of Directors on August 23, 2019, it has been determined by the Board of Directors that, as these shares were erroneously issued in October 2018, they should be removed from stated results as at February 28, 2019, notwithstanding that the actual cancellation was effected on August 23, 2019.

8. Preferred Stock (Details)

8. Preferred Stock (Details) - $ / shares	Feb. 28, 2019	Jan. 11, 2019	Feb. 28, 2018	Feb. 18, 2016	Nov. 04, 2015
Series A Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Preferred Stock, Shares Issued	2,000,000
Series B Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Preferred Stock, Shares Issued	0		2,000,000	1,000,000	2,000,000
Preferred Stock, Shares Authorized	2,000,000		2,000,000
Series C Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Preferred Stock, Shares Issued	0		995,600
Preferred Stock, Shares Authorized	2,000,000		2,000,000
Preferred Shares Cancelled		995,600
Series D Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized	2,000,000		2,000,000

9. Convertible Promissory Note

9. Convertible Promissory Note (Details)	12 Months Ended
	Feb. 28, 2019USD ($)
Details
Debt Instrument, Issuance Date	Jun. 24, 2014
Debt Instrument, Issuer	Company
Debt Instrument, Description	Convertible Promissory Note
Debt Instrument, Face Amount	$ 1,105,000

10. Securities Purchase Agree_2

10. Securities Purchase Agreement (Details) - USD ($)	Feb. 28, 2019	Feb. 18, 2016	Sep. 17, 2014	Aug. 29, 2014
Securities Purchase Agreement, Gross Proceeds			$ 500,000	$ 100,000
Securities Purchase Agreement, Financing Fees	$ 18,000		$ 52,000
Series B Preferred Shares
Preferred Stock, Shares Issued		1,000,000

11. Subsequent Events (Details)

11. Subsequent Events (Details)	12 Months Ended
	Feb. 28, 2019USD ($)shares
Debt Instrument, Description	Convertible Promissory Note
Debt Instrument, Face Amount | $	$ 1,105,000
Event #1
Subsequent Event, Date	Apr. 2, 2019
Subsequent Event, Description	we issued 151,216 common stock shares
Stock Issued During Period, Shares, New Issues	151,216
Event #2
Subsequent Event, Date	Apr. 25, 2019
Subsequent Event, Description	we issued 100,000 common stock shares
Stock Issued During Period, Shares, New Issues	100,000
Event #3
Subsequent Event, Date	May 1, 2019
Subsequent Event, Description	we signed a Memorandum of Understanding with the Ministry of Health on behalf of The Republic of Vanuatu for the purposes of establishing a public-private partnership for the health and well-being of Ni-Vanuatu people
Event #4
Subsequent Event, Date	May 9, 2019
Subsequent Event, Description	we issued 155,452 common stock shares
Stock Issued During Period, Shares, New Issues	155,452
Event #5
Subsequent Event, Date	May 24, 2019
Subsequent Event, Description	we issued 126,990 common stock shares
Stock Issued During Period, Shares, New Issues	126,990
Event #6
Subsequent Event, Date	May 30, 2019
Subsequent Event, Description	we signed a Memorandum of Understanding with the Ministry of Agriculture on behalf of The Republic of Vanuatu for the purposes of establishing a public-private partnership
Event #7
Subsequent Event, Date	May 30, 2019
Subsequent Event, Description	we signed a Memorandum of Understanding with the Ministry of Agriculture on behalf of The Republic of Vanuatu for the purposes to establish the terms and conditions
Event #8
Subsequent Event, Date	Jun. 17, 2019
Subsequent Event, Description	we entered into a 10% Convertible Promissory Note (the “Note”) for the Principal Sum of $220,000 by and between the Company and Harbor Gates Capital, LLC (the “Holder”)
Debt Instrument, Description	a 10% Convertible Promissory Note
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Face Amount | $	$ 220,000
Event #9
Subsequent Event, Date	Jun. 24, 2019
Subsequent Event, Description	we issued 28,500 common stock shares
Stock Issued During Period, Shares, New Issues	28,500
Event #10
Subsequent Event, Date	Jun. 24, 2019
Subsequent Event, Description	the Board of Directors granted Martin Tindall a temporary leave of absence from his position as Chief Executive Officer
Event #11
Subsequent Event, Date	Jul. 11, 2019
Subsequent Event, Description	the Board of Directors confirmed that Martin Tindall had been arrested and charged with securities fraud in the State of Colorado
Event #12
Subsequent Event, Date	Jul. 23, 2019
Subsequent Event, Description	we issued 92,690 common shares
Stock Issued During Period, Shares, New Issues	92,690
Event #13
Subsequent Event, Date	Aug. 5, 2019
Subsequent Event, Description	Michael Gobel resigned as Director of the Company
Event #14
Subsequent Event, Date	Aug. 22, 2019
Subsequent Event, Description	we issued 40,000 Series B Preferred Shares (the “Preferred Shares”) to entities associated with each of the five members of a Special Committee
Event #15
Subsequent Event, Date	Aug. 27, 2019
Subsequent Event, Description	our Board permanently removed Martin Tindall as our Chief Executive Officer
Event #16
Subsequent Event, Date	Aug. 27, 2019
Subsequent Event, Description	we issued 22,667 common shares
Stock Issued During Period, Shares, New Issues	22,667
Event #17
Subsequent Event, Date	Nov. 11, 2019
Subsequent Event, Description	Constantine and Suzanne Makris were granted a default judgement against the Company

12. Commitments and Contingen_2

12. Commitments and Contingencies (Details)	12 Months Ended
	Feb. 28, 2019USD ($)
Contingency #1
Loss Contingency, Lawsuit Filing Date	October 29, 2018
Loss Contingency, Name of Plaintiff	Gauntlet Holdings, LLC (“Gauntlet”) and NMS Capital Advisors, LLC (“NMS”)
Loss Contingency, Name of Defendant	us and our then Chief Executive Officer, Martin Tindall
Loss Contingency, Allegations	breach of contract and fraudulent misrepresentation in connection with an alleged default upon a Secured Promissory Note
Loss Contingency, Domicile of Litigation	Superior Court of California, Los Angeles-Central District
Loss Contingency, Recorded Liability	$ 100,000
Contingency #2
Loss Contingency, Lawsuit Filing Date	January 30, 2019
Loss Contingency, Name of Plaintiff	Terrence Roderick Hannam
Loss Contingency, Name of Defendant	us
Loss Contingency, Allegations	breach of contract in connection with an agreement that we would acquire all shares of Silver Holdings, Ltd.
Loss Contingency, Domicile of Litigation	Supreme Court of Republic of Vanuatu
Loss Contingency, Actions Taken by Defendant	We have filed a Motion to Dismiss regarding this litigation.